研究者業績

平井 啓之

ヒライ ケイジ  (Keiji Hirai)

基本情報

所属
自治医科大学 腎臓内科 / 医学部総合医学第1講座 准教授

研究者番号
20800783
ORCID ID
 https://orcid.org/0000-0002-6899-2478
J-GLOBAL ID
202101020620789997
researchmap会員ID
R000026631

学歴

 1

論文

 81
  • Katsunori Yanai, Keiji Hirai, Taisuke Kitano, Haruhisa Miyazawa, Kiyonori Ito, Susumu Ookawara, Yoshiyuki Morishita
    Clinical and Experimental Nephrology 2025年4月16日  
  • Junki Morino, Keiji Hirai, Katsuyuki Yoshida, Shinichi Kako, Susumu Ookawara, Hisashi Oshiro, Hitoshi Sugawara, Yoshiyuki Morishita
    Cureus 2025年3月8日  
  • 小藤 誠也, 伊藤 聖学, 梅田 千典, 岡田 ひとみ, 谷中田 佳昭, 草浦 理恵, 森野 諄紀, 睦好 祐子, 北野 泰佑, 宮澤 晴久, 神尾 直, 方山 真朱, 平井 啓之, 大河原 晋, 森下 義幸
    埼玉透析医学会会誌 13(2) 90-90 2024年11月  
  • Kae Sunagawa, Keiji Hirai, Sumito Sunagawa, Norifumi Kamiya, Isao Komesu, Yusako Sunagawa, Hiroshi Sunagawa, Ken Nakachi, Aizan Hirai, Susumu Ookawara, Yoshiyuki Morishita
    Diabetes, Metabolic Syndrome and Obesity 2024年10月  
  • Keiji Hirai, Taisuke Kitano, Keiji Nakayama, Fujiko Morita, Hajime Satomura, Takahisa Tanaka, Toru Yoshioka, Masahiko Matsumoto, Yuichi Kimura, Taku Shikanai, Koji Sasaki, Zhiying Zhang, Kiyonori Ito, Susumu Ookawara, Yoshiyuki Morishita
    Journal of Clinical Medicine 2024年7月18日  
  • Keiji Hirai, Masako Shimotashiro, Toshiaki Okumura, Susumu Ookawara, Yoshiyuki Morishita
    Kidney Research and Clinical Practice 2024年5月31日  
  • Keiji Hirai, Masako Shimotashiro, Toshiaki Okumura, Susumu Ookawara, Yoshiyuki Morishita
    International Journal of Nephrology and Renovascular Disease 2024年5月  
  • Junki Morino, Keiji Hirai, Yoshiyuki Morishita
    Clinical Case Reports 2024年5月  
  • Junki Morino, Keiji Hirai, Yoshiyuki Morishita
    Oxford Medical Case Reports 2024年3月1日  
  • Yusaku Watanabe, Keiji Hirai, Momoko Hirata, Taisuke Kitano, Kiyonori Ito, Susumu Ookawara, Hisashi Oshiro, Yoshiyuki Morishita
    BMC nephrology 25(1) 53-53 2024年2月9日  
    BACKGROUND: Minimal change nephrotic syndrome (MCNS) can be complicated by thymoma; however, no standard therapy for thymoma-associated MCNS has yet been established. We herein describe a case of steroid-resistant MCNS associated with thymoma, treated effectively with rituximab. CASE PRESENTATION: A 71-year-old Japanese man was referred to our department with severe proteinuria (20 g/gCr). Renal biopsy showed minimal change disease and computed tomography revealed an anterior mediastinal mass. Based on these findings, he was diagnosed with thymoma-associated MCNS. He was treated with oral prednisolone (50 mg/day) and cyclosporine, and underwent thymectomy and plasma exchange. However, no improvement in proteinuria was observed. He therefore received intravenous rituximab 500 mg, resulting in a marked decrease in proteinuria from 5328 to 336 mg/day after 1 week. CONCLUSIONS: This case suggests that rituximab might be an effective therapy in patients with steroid-resistant MCNS associated with thymoma.
  • Susumu Ookawara, Kiyonori Ito, Yusuke Sasabuchi, Yuichiro Ueda, Junki Morino, Shohei Kaneko, Yuko Mutsuyoshi, Taisuke Kitano, Keiji Hirai, Yoshiyuki Morishita
    Kidney & blood pressure research 49(1) 368-376 2024年  
    INTRODUCTION: Clinical studies on differences among changes in cerebral and hepatic oxygenation during hemodialysis (HD) in patients with and without intradialytic hypotension (IDH) are limited. We investigated changes in intradialytic cerebral and hepatic oxygenation before systolic blood pressure (SBP) reached the nadir during HD and compared these differences between patients with and without symptomatic IDH. METHODS: We analyzed data from 109 patients with (n = 23) and without (n = 86) symptomatic IDH who were treated with HD. Cerebral and hepatic regional oxygen saturation (rSO2), as a marker of tissue oxygenation and circulation, was monitored during HD using an INVOS 5100c oxygen saturation monitor. Changes in cerebral or hepatic rSO2 when SBP reached the nadir during HD were compared between the groups of patients. RESULTS: The cerebral rSO2 before HD in patients with and without symptomatic IDH was 49.7 ± 11.2% and 51.3 ± 9.1% (p = 0.491). %Changes in cerebral rSO2 did not significantly differ between the two groups from 60 min before the SBP nadir during HD. Hepatic rSO2 before HD in patients with and without symptomatic IDH was 58.5 ± 15.4% and 57.8 ± 15.9% (p = 0.869). The %changes in hepatic rSO2 were significantly lower in patients with symptomatic IDH than in those without throughout the observational period (p < 0.001). We calculated the area under the receiver operating characteristic curve (AUC) and estimated cutoff values for changes in hepatic rSO2 as a symptomatic IDH predictor. The predictive ability at 5 and 40 min before symptomatic IDH onset was excellent, with AUCs and cutoff values of 0.847 and 0.841, and -10.9% and -5.0%, respectively. CONCLUSIONS: Hepatic oxygenation significantly decreased more in patients with symptomatic IDH before its onset, than in those without symptomatic IDH, whereas changes in cerebral oxygenation did not differ. Evaluating changes in hepatic oxygenation during HD might help to predict symptomatic IDH.
  • Katsunori Yanai, Shohei Kaneko, Akinori Aomatsu, Keiji Hirai, Susumu Ookawara, Yoshiyuki Morishita
    Diagnostics 2023年12月13日  
  • Katsunori Yanai, Keiji Hirai, Shohei Kaneko, Yuko Mutsuyoshi, Taisuke Kitano, Haruhisa Miyazawa, Kiyonori Ito, Yuichiro Ueda, Susumu Ookawara, Yoshiyuki Morishita
    Drug Design, Development and Therapy 2023年11月  
  • Yusaku Watanabe, Keiji Hirai, Momoko Matsuyama, Taisuke Kitano, Kiyonori Ito, Tsuyoshi Kobashigawa, Susumu Ookawara, Yoshiyuki Morishita
    The Journal of international medical research 51(9) 3000605231200272-3000605231200272 2023年9月  
    Only a few cases of renal vein thrombosis (RVT) occurring in patients with vasculitis have been reported. RVT associated with vasculitis and hemolytic anemia has not been reported yet. We describe here a patient with RVT complicated by pulmonary embolism, autoimmune hemolytic anemia, and eosinophilic granulomatous polyangiitis. A 69-year-old Japanese man who had been treated with corticosteroids was referred to our department for severe proteinuria (4.32 g/gCr). Abdominal ultrasonography showed bilateral RVT, and contrast-enhanced computed tomography showed bilateral pulmonary embolism. Therefore, the patient was diagnosed with RVT complicated by pulmonary embolism. Anticoagulation therapy with heparin followed by apixaban was started. Thereafter, the D-dimer concentration decreased from 8.3 to 1.2 μg/mL, and urinary protein excretion improved to 0.62 g/gCr. Renal function was unchanged with an estimated glomerular filtration rate of 68.8 mL/minute/1.73 m2. The thrombi in both renal veins and pulmonary arteries gradually regressed. Clinicians should be aware of this complication when worsening proteinuria is observed during steroid therapy in patients with autoimmune hemolytic anemia and eosinophilic granulomatous polyangiitis.
  • Shohei Kaneko, Susumu Ookawara, Kiyonori Ito, Saori Minato, Yuko Mutsuyoshi, Yuichiro Ueda, Keiji Hirai, Yoshiyuki Morishita
    Journal of Clinical Medicine 2023年6月21日  
  • Susumu Ookawara, Kiyonori Ito, Yuichiro Ueda, Saori Minato, Shohei Kaneko, Momoko Hirata, Taisuke Kitano, Haruhisa Miyazawa, Keiji Hirai, Yoshiyuki Morishita
    The International Journal of Artificial Organs 2023年5月  
  • Shohei Kaneko, Katsunori Yanai, Hiroki Ishii, Akinori Aomatsu, Keiji Hirai, Susumu Ookawara, Kenichi Ishibashi, Yoshiyuki Morishita
    International Journal of Molecular Sciences 2022年12月6日  
  • Keiji Hirai, Masako Shimotashiro, Tokio Sonoda, Toshiaki Okumura, Susumu Ookawara, Yoshiyuki Morishita
    Clinical and experimental nephrology 26(9) 925-932 2022年9月  
    BACKGROUND: We investigated factors associated with the anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike antibody titer after the second dose of the BNT162b2 messenger RNA coronavirus disease 2019 (COVID-19) vaccine in Japanese patients undergoing hemodialysis. METHODS: Overall, 75 patients (41 men, 34 women; mean age 71.4 ± 12.2 years) with a hemodialysis duration of 5.7 ± 6.1 [interquartile range, 1.0-8.5] years were enrolled in this single-center, prospective, cross-sectional study. We used multiple linear regression analysis to determine the relationships of the anti-SARS-CoV-2 spike antibody titer with patient demographic and clinical parameters. We also compared the anti-SARS-CoV-2 spike antibody titer between hemodialysis patients and 22 healthcare workers (10 men, 12 women; mean age 48.5 ± 14.4 years). RESULTS: Autoimmune disease presence (standard coefficient [β] =  - 0.290, p = 0.018), lymphocyte counts (β = 0.261, p = 0.015), hemoglobin levels (β = 0.290, p = 0.009), and blood urea nitrogen concentrations (β = 0.254, p = 0.033) were significantly and independently correlated with the log-anti-SARS-CoV-2 spike antibody titer. The anti-SARS-CoV-2 spike antibody titer was significantly lower in hemodialysis patients than in healthcare workers (3589 ± 3921 [813-4468] vs. 12,634 ± 18,804 [3472-10,257] AU/mL; p < 0.002). CONCLUSIONS: Autoimmune disease presence, lymphocyte counts, hemoglobin levels, and blood urea nitrogen concentrations were associated with the anti-SARS-CoV-2 spike antibody titer after the second dose of the BNT162b2 messenger RNA COVID-19 vaccine in Japanese patients undergoing hemodialysis.
  • Hisashi Sato, Susumu Ookawara, Kiyonori Ito, Yuichiro Ueda, Keiji Hirai, Yoshikazu Yoshino, Yoshiyuki Morishita
    Radiology case reports 17(8) 2589-2593 2022年8月  
    A 68-year-old man received hemodialysis (HD) for the treatment of end-stage renal failure for 6 years. Five years prior to carotid artery stenting (CAS), a neck ultrasound performed to screen for carotid atherosclerosis revealed an asymptomatic right internal carotid artery stenosis. One month prior, the stenotic lesion progressed to 74% by cerebral angiography; therefore, CAS was performed. To evaluate the influence of right internal carotid artery stenosis on the intradialytic cerebral circulation and oxygenation, cerebral regional oxygen saturation (rSO2) at bilateral forehead was measured using the INVOS 5100c oxygen saturation monitor (Covidien Japan, Japan) during HD before and after CAS. Before CAS, right cerebral rSO2 was maintained during HD, whereas left cerebral rSO2 gradually increased from the initiation to end of HD. However, the differences of intradialytic cerebral rSO2 changes between bilateral sides disappeared after CAS. In the present case, before CAS, the intradialytic increase in left cerebral rSO2 might reflect the increase in the left cerebral blood flow to compensate for the ultrafiltration-associated decreases in the right cerebral blood flow and perfusion pressure. Furthermore, the preserved right cerebral rSO2 before CAS might reflect the mechanism maintaining the right cerebral blood flow from the collateralized circle of Willis during HD. Throughout our experience, cerebral oxygenation monitoring during HD might disclose intradialytic changes in cerebral blood flow distribution between the ipsilateral and contralateral side in HD patients with carotid artery stenosis.
  • Junya Nishihata, Keiji Hirai, Hiroki Yabe, Yoshiyuki Morishita
    BMJ case reports 15(4) 2022年4月1日  
  • Keiji Hirai, Shigeki Imamura, Aizan Hirai, Naoka Umemoto, Hisashi Oshiro, Fuyuki Kametani, Nagaaki Katoh, Masahide Yazaki, Susumu Ookawara, Yoshiyuki Morishita
    Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 29(3) 1-3 2022年3月7日  
  • Ibuki Kurihara, Keiji Hirai, Susumu Ookawara, Akira Tanaka, Tsuneaki Kenzaka, Hitoshi Sugawara
    American Journal of Case Reports 23 2022年2月2日  査読有り
  • Shohei Kaneko, Katsunori Yanai, Taisuke Kitano, Haruhisa Miyazawa, Keiji Hirai, Susumu Ookawara, Yoshiyuki Morishita
    Frontiers in Medicine 8 2021年11月5日  
  • Hiroki Ishii, Shohei Kaneko, Katsunori Yanai, Akinori Aomatsu, Keiji Hirai, Susumu Ookawara, Yoshiyuki Morishita
    Translational Research 237 31-52 2021年11月1日  
  • Taisuke Kitano, Kiyonori Ito, Susumu Ookawara, Taro Hoshino, Hideyuki Hayasaka, Masaya Kofuji, Takayuki Uchida, Junki Morino, Saori Minato, Shohei Kaneko, Katsunori Yanai, Yuko Mutsuyoshi, Hiroki Ishii, Momoko Matsuyama-Hirata, Mitsutoshi Shindo, Haruhisa Miyazawa, Yuichiro Ueda, Keiji Hirai, Yoshiyuki Morishita
    International Journal of Artificial Organs 44(11) 822-828 2021年11月1日  
  • Keiji Hirai, Hiroaki Nonaka, Moeka Ueda, Junki Morino, Shohei Kaneko, Saori Minato, Yuko Mutsuyoshi, Katsunori Yanai, Hiroki Ishii, Momoko Matsuyama, Taisuke Kitano, Akinori Aomatsu, Haruhisa Miyazawa, Kiyonori Ito, Yuichiro Ueda, Susumu Ookawara, Yoshiyuki Morishita
    Pragmatic and Observational Research 12 81-91 2021年8月  
    PURPOSE: We compared the efficacy of teneligliptin versus linagliptin for glycemic control and renoprotection in patients with advanced-stage diabetic kidney disease. PATIENTS AND METHODS: Changes in the glycated hemoglobin (HbA1c), fasting blood glucose concentration, urine albumin-to-creatinine ratio (UACR), and estimated glomerular filtration rate (eGFR) during a 12-month period were retrospectively analyzed after switching from linagliptin to teneligliptin in 13 patients with advanced-stage diabetic kidney disease (teneligliptin group). Thirteen propensity score-matched patients who were treated with linagliptin alone served as controls (linagliptin group). RESULTS: The HbA1c, fasting blood glucose concentration, and UACR did not change during the 12-month study period in either group. The annual change rate in the eGFR did not differ between before and after baseline in either group. CONCLUSION: Switching from linagliptin to teneligliptin may not improve glycemic control, reduce urinary protein excretion, or ameliorate the rate of renal function decline in patients with advanced-stage diabetic kidney disease. These results suggest that teneligliptin may not be more advantageous for glycemic control and renoprotection compared with linagliptin in patients with advanced-stage diabetic kidney disease.
  • Mitsutoshi Shindo, Kenichi Oguchi, Chihiro Kimikawa, Kiyonori Ito, Jyunki Morino, Saori Minato, Haruhisa Miyazawa, Keiji Hirai, Susumu Ookawara, Yoshiyuki Morishita
    Journal of Vascular Access 22(3) 488-491 2021年5月1日  
  • Keiji Hirai, Susumu Ookawara, Momoko Matsuyama, Taisuke Kitano, Kiyonori Ito, Yuichiro Ueda, Tatsuro Watano, Shinji Fujino, Kiyoka Omoto, Yoshiyuki Morishita
    Cureus 13(3) e14119 2021年3月25日  
    Background Few studies have assessed the relationship between serum total carbon dioxide (CO2) and bicarbonate ion (HCO3 -) concentration in patients undergoing peritoneal dialysis. We determined the agreement between serum total CO2 and HCO3 - concentration and the diagnostic accuracy of serum total CO2 for the prediction of low (HCO3 - <24 mEq/L) and high (HCO3 - ≥24 mEq/L) bicarbonate concentrations in patients on peritoneal dialysis. Methods We collected 245 samples of venous blood from 51 patients on peritoneal dialysis. Independent factors that correlated with the HCO3 - concentration were analyzed using multiple linear regression analysis. The diagnostic accuracy of serum total CO2 was evaluated by receiver operating characteristic (ROC) curve analysis and a 2×2 table. Agreement between serum total CO2 and HCO3 - concentration was assessed by Bland-Altman analysis. Results Serum total CO2 was independently correlated with HCO3 - concentration (β = 0.354, p < 0.001). The area under the curve of serum total CO2 for the identification of low and high bicarbonate concentrations was 0.909. The diagnostic accuracy of serum total CO2 for the prediction of low and high bicarbonate concentrations was: sensitivity, 91.5%; specificity, 74.7%; positive predictive value, 53.5%; negative predictive value, 96.5%; and accuracy, 78.8%. Bland-Altman analysis showed a moderate agreement between serum total CO2 and HCO3 - concentration. Conclusion Serum total CO2 correlated closely with the HCO3 - concentration in patients undergoing peritoneal dialysis. Serum total CO2 might be useful for predicting low and high bicarbonate in peritoneal dialysis patients.
  • Yuko Mutsuyoshi, Keiji Hirai, Junki Morino, Shohei Kaneko, Saori Minato, Katsunori Yanai, Hiroki Ishii, Momoko Matsuyama, Taisuke Kitano, Akinori Aomatsu, Haruhisa Miyazawa, Kiyonori Ito, Yuichiro Ueda, Susumu Ookawara, Yoshiyuki Morishita
    Medicine 100(10) e25164 2021年3月12日  
  • Susumu Ookawara, Kiyonori Ito, Yusuke Sasabuchi, Yuichiro Ueda, Hideyuki Hayasaka, Masaya Kofuji, Takayuki Uchida, Keita Horigome, Toshiko Aikawa, Satoru Imada, Saori Minato, Haruhisa Miyazawa, Hirofumi Shimoyama, Keiji Hirai, Akihisa Watanabe, Hiromi Shimoyama, Yoshiyuki Morishita
    Nephron 145(2) 171-178 2021年  
    INTRODUCTION: The prevalence of cognitive impairment in patients undergoing hemodialysis (HD) is higher than that in healthy controls. To date, studies on the association between cognitive function and cerebral oxygenation in these patients are limited. Therefore, in this study, we aimed to cross-sectionally investigate the association between cognitive assessment scores and clinical factors, including cerebral oxygenation, in patients undergoing HD. METHODS: In this observational study, 193 HD patients were included. Cerebral regional oxygen saturation (rSO2) was monitored using an INVOS 5,100c oxygen saturation monitor. Poor cognition was defined as a Mini-Mental State Examination (MMSE) score ≤23. We analyzed the association between MMSE score and clinical factors, including cerebral rSO2. RESULTS: MMSE score in HD patients included in this study was 26.8 ± 3.3. There were 164 patients (85%) with MMSE score ≥24 and 29 patients (15%) with an MMSE score ≤23. In the patients with MMSE score ≥24, cerebral rSO2 (53.8% ± 8.3%) was significantly higher than that in patients with MMSE score ≤23 (49.5% ± 9.8%; p = 0.013). Multivariable linear regression analysis was performed using the following confounding factors: age, mean blood pressure, cerebral rSO2, HD duration, ultrafiltration rate, hemoglobin, serum Cr, serum calcium, serum phosphate, total cholesterol, high-density lipoprotein cholesterol levels, serum albumin, presence of diabetes mellitus or chronic glomerulonephritis, history of comorbid cardiovascular or cerebrovascular disease, and use of renin-angiotensin-aldosterone system inhibitors or vitamin D analogs. MMSE score was independently and significantly associated with age (standardized coefficient: -0.244) and cerebral rSO2 (standardized coefficient: 0.180). CONCLUSIONS: MMSE score was independently associated with age (negative effect) and cerebral rSO2 (positive effect) in this cross-sectional study. Further prospective studies are needed to clarify whether maintaining cerebral oxygenation prevents the deterioration of cognitive function in patients undergoing HD.
  • Yuichiro Ueda, Susumu Ookawara, Kiyonori Ito, Yusuke Sasabuchi, Hideyuki Hayasaka, Masaya Kofuji, Takayuki Uchida, Sojiro Imai, Satoshi Kiryu, Saori Minato, Haruhisa Miyazawa, Hidenori Sanayama, Keiji Hirai, Kaoru Tabei, Yoshiyuki Morishita
    PloS one 16(10) e0259064 2021年  
    The hepato-splanchnic circulation directly influences oxygenation of the abdominal organs and plays an important role in compensating for the blood volume reduction that occurs in the central circulation during hemodialysis (HD) with ultrafiltration. However, the hepato-splanchnic circulation and oxygenation cannot be easily evaluated in the clinical setting of HD therapy. We included 185 HD patients and 15 healthy volunteers as the control group in this study. Before HD, hepatic regional oxygen saturation (rSO2), a marker of hepatic oxygenation reflecting the hepato-splanchnic circulation and oxygenation, was monitored using an INVOS 5100c oxygen saturation monitor. Hepatic rSO2 was significantly lower in patients undergoing HD than in healthy controls (56.4 ± 14.9% vs. 76.2 ± 9.6%, p < 0.001). Multivariable regression analysis showed that hepatic rSO2 was independently associated with body mass index (BMI; standardized coefficient: 0.294), hemoglobin (Hb) level (standardized coefficient: 0.294), a history of cardiovascular disease (standardized coefficient: -0.157), mean blood pressure (BP; standardized coefficient: 0.154), and serum albumin concentration (standardized coefficient: 0.150) in Model 1 via a simple linear regression analysis. In Model 2 using the colloid osmotic pressure (COP) in place of serum albumin concentration, the COP (standardized coefficient: 0.134) was also identified as affecting hepatic rSO2. Basal hepatic oxygenation before HD might be affected by BMI, Hb levels, a history of cardiovascular disease, mean BP, serum albumin concentration, and the COP. Further prospective studies are needed to clarify whether changes in these parameters, including during HD, affect the hepato-splanchnic circulation and oxygenation in HD patients.
  • Keiji Hirai, Hiroaki Nonaka, Moeka Ueda, Junki Morino, Shohei Kaneko, Saori Minato, Yuko Mutsuyoshi, Katsunori Yanai, Hiroki Ishii, Momoko Matsuyama, Taisuke Kitano, Akinori Aomatsu, Haruhisa Miyazawa, Kiyonori Ito, Yuichiro Ueda, Susumu Ookawara, Yoshiyuki Morishita
    Frontiers in medicine 8 667117-667117 2021年  
    Background: We investigated the effects of roxadustat on the anemia, iron metabolism, peritoneal membrane function, and residual renal function; and determined the factors associated with the administration of roxadustat in patients who were undergoing peritoneal dialysis. Methods: We retrospectively analyzed the changes in hemoglobin, serum ferritin, transferrin saturation (TSAT), 4-h dialysate/plasma creatinine, and renal weekly urea clearance over the 24 weeks following the change from an erythropoiesis-stimulating agent (ESA) to roxadustat in 16 patients who were undergoing peritoneal dialysis and had anemia (Roxadustat group). Twenty-three peritoneal dialysis patients who had anemia and continued ESA served as a control group (ESA group). Results: There were no significant differences in hemoglobin, serum ferritin, TSAT, 4-h dialysate/plasma creatinine, or renal weekly urea clearance between the two groups at baseline. The hemoglobin concentration was significantly higher in the Roxadustat group than in the ESA group after 24 weeks (11.6 ± 1.0 g/dL vs. 10.3 ± 1.1 g/dL, p < 0.05), whereas the ferritin concentration and TSAT were significantly lower (139.5 ± 102.0 ng/mL vs. 209.2 ± 113.1 ng/mL, p < 0.05; and 28.1 ± 11.5% vs. 44.8 ± 10.4%, p < 0.05, respectively). The changes in 4-h dialysate/plasma creatinine and renal weekly urea clearance did not differ between the two groups. Linear regression analysis revealed that the serum potassium concentration correlated with the dose of roxadustat at 24 weeks (standard coefficient = 0.580, p = 0.019). Conclusion: Roxadustat may improve the anemia and reduce the serum ferritin and TSAT of the peritoneal dialysis patients after they were switched from an ESA, without association with peritoneal membrane function or residual renal function.
  • Momoko Matsuyama, Keiji Hirai, Hiroaki Nonaka, Moeka Ueda, Junki Morino, Shohei Kaneko, Saori Minato, Yuko Mutsuyoshi, Katsunori Yanai, Hiroki Ishii, Taisuke Kitano, Akinori Aomatsu, Haruhisa Miyazawa, Kiyonori Ito, Yuichiro Ueda, Susumu Ookawara, Yoshiyuki Morishita
    Frontiers in medicine 8 780127-780127 2021年  
    OBJECTIVE: The aim of this study was to investigate the effects of elobixibat on constipation and lipid metabolism; and determine the factors associated with the effect of elobixibat on constipation in patients with moderate to end-stage chronic kidney disease (CKD). METHODS: Stool frequency and serum lipid parameters were retrospectively analyzed before and after 4 weeks of elobixibat administration in 42 patients (CKD stage G3, 6; stage G4, 9; stage G5, 9; stage G5D, 18). Relationships between the change in stool frequency after initiation of elobixibat and various clinical parameters were analyzed by using linear regression analysis. RESULTS: Elobixibat increased stool frequency from 0.5 ± 0.4 per day to 1.1 ± 0.6 per day (p < 0.001) regardless of whether patients were undergoing dialysis, on concomitant laxatives, or were administered elobixibat before or after breakfast. Elobixibat reduced low-density lipoprotein cholesterol concentration (from 90.9 ± 37.2 mg/dL to 77.5 ± 34.8 mg/dL, p < 0.05) and increased high-density lipoprotein cholesterol concentration (from 44.9 ± 14.3 mg/dL to 57.0 ± 25.8 mg/dL, p < 0.05), but did not change triglyceride concentration. Adverse effects were observed in two patients (nausea and diarrhea). Only phosphate concentration was correlated with the change in stool frequency after initiation of elobixibat (standard coefficient = 0.321, p = 0.043). CONCLUSIONS: Elobixibat improved constipation and lipid metabolism in patients with moderate to end-stage CKD, without serious adverse events.
  • Keiji Hirai, Susumu Ookawara, Junki Morino, Saori Minato, Shohei Kaneko, Katsunori Yanai, Hiroki Ishii, Momoko Matsuyama, Taisuke Kitano, Mitsutoshi Shindo, Haruhisa Miyazawa, Kiyonori Ito, Yuichirou Ueda, Tatsuro Watano, Shinji Fujino, Kiyoka Omoto, Yoshiyuki Morishita
    Kidney Research and Clinical Practice 2020年12月31日  
  • Keiji Hirai, Shigeki Imamura, Aizan Hirai, Susumu Ookawara, Yoshiyuki Morishita
    Journal of Clinical Medicine 2020年10月18日  
  • Kiyonori Ito, Susumu Ookawara, Takayuki Uchida, Hideyuki Hayasaka, Masaya Kofuji, Haruhisa Miyazawa, Akinori Aomatsu, Yuichiro Ueda, Keiji Hirai, Yoshiyuki Morishita
    Journal of Visualized Experiments 2020(164) 1-8 2020年10月1日  
  • Keiji Hirai, Junki Morino, Saori Minato, Shohei Kaneko, Katsunori Yanai, Yuko Mutsuyoshi, Hiroki Ishii, Momoko Matsuyama, Taisuke Kitano, Akinori Aomatsu, Haruhisa Miyazawa, Kiyonori Ito, Yuichiro Ueda, Susumu Ookawara, Yoshiyuki Morishita
    Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2020年10月  
  • Shohei Kaneko, Junki Morino, Saori Minato, Katsunori Yanai, Yuko Mutsuyoshi, Hiroki Ishii, Momoko Matsuyama, Taisuke Kitano, Mitsutoshi Shindo, Akinori Aomatsu, Haruhisa Miyazawa, Yuichiro Ueda, Kiyonori Ito, Keiji Hirai, Susumu Ookawara, Yoshiyuki Morishita
    Frontiers in Medicine 7 2020年9月17日  
  • Akinori Aomatsu, Keiji Hirai, Hiroki Ishii, Katsunori Yanai, Shohei Kaneko, Yoshiyuki Morishita
    Journal of Visualized Experiments 2020(163) 1-12 2020年9月1日  
  • Susumu Ookawara, Kiyonori Ito, Yusuke Sasabuchi, Hideyuki Hayasaka, Masaya Kofuji, Takayuki Uchida, Keita Horigome, Sojiro Imai, Toshiko Akikawa, Noriko Wada, Satoshi Kiryu, Satoru Imada, Mitsutoshi Shindo, Haruhisa Miyazawa, Keiji Hirai, Yasushi Onishi, Hirofumi Shimoyama, Akihisa Watanabe, Kaoru Tabei, Yoshiyuki Morishita
    PLoS ONE 15(8) 2020年8月1日  
  • Hiroki Ishii, Chiaki Miyoshi, Keiji Hirai, Junki Morino, Saori Minato, Shohei Kaneko, Katsunori Yanai, Momoko Matsuyama, Taisuke Kitano, Mitsutoshi Shindo, Akinori Aomatsu, Hiroshi Shimoyama, Haruhisa Miyazawa, Kiyonori Ito, Yuichiro Ueda, Yoshio Kaku, Taro Hoshino, Susumu Ookawara, Yoshiyuki Morishita
    CEN case reports 9(3) 225-231 2020年8月1日  
  • Keiji Hirai, Shigeki Imamura, Aizan Hirai, Susumu Ookawara, Yoshiyuki Morishita
    Journal of Clinical Medicine 2020年7月16日  
  • Shohei Kaneko, Katsunori Yanai, Hiroki Ishii, Akinori Aomatsu, Kiyonori Ito, Keiji Hirai, Susumu Ookawara, Kenichi Ishibashi, Yoshiyuki Morishita
    Journal of Visualized Experiments 2020(161) 1-8 2020年7月1日  
  • Saori Minato, Haruhisa Miyazawa, Taisuke Kitano, Mitsutoshi Shindo, Kiyonori Ito, Yuichiro Ueda, Keiji Hirai, Taro Hoshino, Susumu Ookawara, Yoshiyuki Morishita
    Peritoneal Dialysis International 40(4) 419-421 2020年7月1日  
  • Hiroki Ishii, Satoshi Kurihara, Keiji Hirai, Katsunori Yanai, Susumu Ookawara, Yoshiyuki Morishita
    Medicine 99(25) e20724 2020年6月19日  
  • Taisuke Kitano, Kiyonori Ito, Susumu Ookawara, Mitsutoshi Shindo, Takayuki Uchida, Masaya Kofuji, Hideyuki Hayasaka, Haruhisa Miyazawa, Yuichiro Ueda, Keiji Hirai, Taro Hoshino, Yoshiyuki Morishita
    Journal of Artificial Organs 23(2) 187-190 2020年6月1日  
  • Katsunori Yanai, Shohei Kaneko, Hiroki Ishii, Akinori Aomatsu, Kiyonori Ito, Keiji Hirai, Susumu Ookawara, Kenichi Ishibashi, Yoshiyuki Morishita
    Frontiers in Medicine 7 2020年1月1日  
  • Shohei Kaneko, Keiji Hirai, Junki Morino, Saori Minato, Katsunori Yanai, Yuko Mutsuyoshi, Hiroki Ishii, Momoko Matsuyama, Taisuke Kitano, Mitsutoshi Shindo, Akinori Aomatsu, Haruhisa Miyazawa, Yuichiro Ueda, Kiyonori Ito, Susumu Ookawara, Yoshiyuki Morishita
    Renal Failure 42(1) 146-153 2020年1月1日  
  • Keiji Hirai, Junki Morino, Saori Minato, Shohei Kaneko, Katsunori Yanai, Yuko Mutsuyoshi, Hiroki Ishii, Momoko Matsuyama, Taisuke Kitano, Mitsutoshi Shindo, Akinori Aomatsu, Haruhisa Miyazawa, Kiyonori Ito, Yuichiro Ueda, Susumu Ookawara, Yoshiyuki Morishita
    Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2020年1月  
  • Junki Morino, Keiji Hirai, Shohei Kaneko, Saori Minato, Katsunori Yanai, Yuko Mutsuyoshi, Hiroki Ishii, Momoko Matsuyama, Taisuke Kitano, Mitsutoshi Shindo, Akinori Aomatsu, Haruhisa Miyazawa, Kiyonori Ito, Yuichiro Ueda, Susumu Ookawara, Yoshiyuki Morishita
    Renal Failure 42(1) 173-178 2020年1月1日  

MISC

 8

共同研究・競争的資金等の研究課題

 1